The EU Commission presents its preliminary results concerning the pharmaceutical sector inquiry raising competition concerns

"Preliminary results of Commission pharmaceutical sector inquiry raise competition concerns"* On 28 November 2008, the Commission presented the preliminary findings of its sector inquiry into pharmaceuticals. The report [1] shows that originator companies engage in practices that can contribute to delayed generic entry. The report also states that originator companies use patent strategies aimed at blocking or delaying the development of novel medicines by competitors. This article explains the rationale for launching the sector inquiry and presents the preliminary findings. I. Context The pharmaceutical sector is essential for the health of Europe’s citizens, who need access to innovative, safe and affordable medicines. A lot of money is at stake: each European consumer paid almost

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • DG GROW (Brussels)
  • EU Delegation to the OECD and UNESCO (Paris)
  • DG COMP (Brussels)

Citation

Fabio Domanico, Elena Kamilarova, Alexander Riedl, The EU Commission presents its preliminary results concerning the pharmaceutical sector inquiry raising competition concerns, 28 novembre 2008, e-Competitions November 2008, Art. N° 35137

Visites 387

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues